Digestery
Longevity supplements › Rapamycin and Aging › Studies

Population study: one-time survey

Survey of 333 adults who used rapamycin off-label and 172 who never did

Kaeberlein and colleagues · GeroScience · 2023

Original title: Evaluation of off-label rapamycin use to promote healthspan in 333 adults.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

No direction

Survey of 333 adults who used rapamycin off-label and 172 who never did. Authors report initial evidence that rapamycin can be used safely in adults of normal health. No aging results given.

The study at a glance

Type of study
Population study: one-time survey
Who or what was studied
505 people · 333 adults who took rapamycin off-label on their own or with a doctor, and 172 who never did
What was tested
Survey comparing people who used rapamycin with people who had not
What it measured
Side effects and safety
Who has a stake
Company stake
Authors co-founded Optispan Geroscience or work for or hold shares in AgelessRX, which sponsors rapamycin trials.
Journal
GeroScience, 2023
Source
PubMed record 37191826. This page is based on the abstract only.

How much this study counts

  • –A one-time snapshot: it shows a link, not a cause, and cannot show which came first.
  • •505 people.
  • •Measured side effects and safety.
  • –Company stake: Authors co-founded Optispan Geroscience or work for or hold shares in AgelessRX, which sponsors rapamycin trials.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    3

    1 benefit, 1 mixed, 1 no difference

  2. Trials in people: other measures

    2

    2 no difference

  3. Trials in people: lab tests or safety

    2

    2 benefit

  4. Population studies

    1

    1 no direction

    ↑ This study is the ringed dot

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    2

    2 benefit

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does rapamycin slow aging in people?”

Not shown in people.

Confidence: very low. Based on 16 on-topic papers.

Read the full answer

Other papers on the same step

None among the papers we read.

See all 16 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The reviewer corrected 2 fields after reading the abstract. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.